CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on May 14, 2007
May
11,
2007
VIA
ELECTRONIC TRANSMISSION AND FACSIMILE
Securities
and Exchange Commission
100
F
Street, N.E.
Washington,
D.C. 20549-6010
|
Re:
|
Lixte
Biotechnology Holdings, Inc. - Registration Statement on Form
SB-2
Registration
No. 333-137208
|
Ladies
and Gentlemen:
On
behalf
of Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”),
the undersigned hereby requests that the Securities and Exchange Commission
issue an order declaring the above-referenced Registration Statement effective
at 4:00 p.m., Washington, D.C. time, on Monday, May 14, 2007, or as soon
thereafter as is practicable.
The
Company hereby acknowledges that:
1. Should
the Commission or the staff, acting pursuant to delegated authority, declare
the
Registration Statement effective, that act will not foreclose the Commission
from taking any action with respect to the filing;
2. The
action of the Commission or the staff, acting pursuant to delegated authority,
in declaring the Registration Statement effective does not relieve the Company
from its full responsibility for the adequacy and accuracy of the disclosures
in
the Registration Statement; and
3. The
Company may not assert staff comments or the declaration of effectiveness as
a
defense in any proceeding initiated by the Commission or any person under the
federal securities laws of the United States.
The
Company also understands that this request for acceleration will be considered
a
confirmation of its awareness of its obligations under the Securities Act of
1933 and the Securities Exchange Act of 1934 with respect to the offering of
securities pursuant to the Registration Statement.
| Very truly yours, | ||
| |
|
|
| By: | /s/ John S. Kovach | |
|
John
S. Kovach
Chief
Executive Officer
Lixte
Biotechnology Holdings, Inc.
|
||